Purpose: The aim of this study was to determine a management strategy for patients with retinal diseases to minimise the potential risk of visual impairment due to the postponement of treatments and visits during the lockdown for COVID-19. Methods: Records of all patients who had rescheduled for retina appointments from March 20, 2020, to June 1, 2020, were identified to evaluate the details regarding best-corrected visual acuity (BCVA) before the COVID-19 pandemic (V0 visit) and at the first visit after lockdown (V1 visit); primary diagnosis, duration of postponement (weeks), change in Snellen line and intravitreal injection (IVI) requirement were recorded. Patients were rescheduled according to our diagnosis-based triage practice pattern; emergency, Group 1; urgent, Group 2; routine, Group 3; and elective, Group 4. BCVA, loss of Snellen line, IVI requirement, and duration of postponement were compared between V0 and V1 visits. In addition, BCVA, change in Snellen line, and the relationship between loss in Snellen line and duration of postponement was evaluated in intravitreally injected patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Results: A total of 1,383 eyes of 763 patients were recruited in this study. The difference in BCVA at V0 visit was statistically significant among the groups and better in Group 4 (p

To evaluate vision-related quality of life (QoL) using National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) in neovascular age-related macular degeneration (nAMD) patients during coronavirus disease-2019 (COVID-19) pandemic. Material and Methods: nAMD patients whose intravitreal injection had to be postponed due to restrictions of COVID-19 lockdown between April and June 2020, NEI-VFQ-25 was administered last visit pre-COVID-19 and first visit during COVID-19. NEI-VFQ-25 scores, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between visits. Results: Fifty six patients with nAMD were participitated in the study. The composite score of NEI-VFQ-25 was statistically significantly lower at first visit during COVID-19 when compared with at last pre-COVID-19 (95% confidence interval, 2.33-4.24; p=0.000). Decrease in NEI-VFQ-25 composite score was moderately associated with an impairment in BCVA at first visit during COVID-19 and duration of treatment delay after adjusting for age, gender, BCVA at last visit pre COVID-19 and CMT (β coefficient=0.42 and 0.41 and p=0.016 and 0.015). Conclusion: Negative impacts of delayed treatment during COVID-19 pandemic were observed by decrease NEI-VFQ-25 composite scores in patients with nAMD observed on psychological well-being and ability of performing daily life activities that depend on visual function.